Amryt Pharma and the FarmaMondo Group sign a new exclusive agreement for two Amryt’s rare disease therapies in the APAC region.

Amryt Pharma and the FarmaMondo Group signed an exclusive partnership agreement for the orphan disease innovative therapies Myalept®, Lojuxta® in the APAC region.

With this new agreement, FarmaMondo extends the partnership signed with Amryt in 2020 for the CIS (Commonwealth of Independent States) countries whereby FarmaMondo will exclusively manage the access of Amryt’s therapies Myalept®, Lojuxta® to patients in Singapore, Hong Kong, Australia, New Zealand, Taiwan, South Korea.

This agreement once again reinforces our strategy and its acceptance by the industry stakeholders. We are proud to have gained such trust from Amryt with this second agreement for a much larger territorial scope. Our growing APAC infrastructure will benefit from the opportunities that this agreement brings.


FarmaMondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.

For more information about FarmaMondo please visit:


Amryt Pharma is a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases. Amryt comprises a profitable and growing commercial business with a significant development pipeline. (Nasdaq: AMYT)

For more information about Amryt Pharma please visit: